Lilly’s Forteo Not A “Rational Choice” For Most Osteoporosis, Analysis Finds
Executive Summary
Lilly's osteoporosis treatment Forteo (teriparatide) would be cost-effective if the product were 60% cheaper and used sequentially with Merck's Fosamax (alendronate), according to a study published in the Archives of Internal Medicine